amgen news - Search News

Amgen says obesity drug caused up to 20% weight loss

Newsweek on MSN · 2h

Amgen Drug Delivers More Weight Loss Than Competitors

A new weight loss drug developed by Amgen may provide better results with fewer injections than current treatments such as Ozempic and Wegovy, according to the results of a recent trial. Trial participants who were obese or overweight lost an average of 20 percent of their body weight in 12 months without their weight loss plateauing,

MarketWatch on MSN · 9h

Amgen’s stock may see worst day in 24 years as weight-loss-drug data underwhelms

Amgen Inc.’s stock was down 7% Tuesday, after the company said a mid-stage trial of its weight-loss treatment MariTide showed up to 20% average weight loss at 52 weeks. Analysts were expecting the treatment to achieve an average weight loss of about 20% to 25% after one year,

Amgen's weight-loss drug fails to impress in study; shares plunge

Amgen's experimental drug MariTide led to an average weight loss of up to 20% in a year-long mid-stage trial of nearly 600 people who were overweight or obese, the company said on Tuesday.

Seeking Alpha12h

Amgen: Checks All The Wrong Boxes

In the case of Amgen (NASDAQ:AMGN), I can honestly say I knew very little about the stock beyond its name and sector for a ...

3h

Amgen price target lowered to $330 from $360 at RBC Capital

RBC Capital analyst Gregory Renza lowered the firm’s price target on Amgen (AMGN) to $330 from $360 and keeps an Outperform rating on the ...

pharmaphorum11h

Amgen's big reveal of obesity data falls a bit flat

William Blair's assessment is that MariTide is an improvement on current obesity therapies with a profile that "will be ...

1d

Amgen Stock Sinks as Obesity Drug Test Results Fail To Meet Expectations

The company reported a Phase 2 study of its injectable MariTide medicine showed an approximately 20% average weight loss over ...

8h

Amgen’s MariTide Phase 2 Success Drives Buy Rating Amid Promising Obesity Treatment Prospects

Goldman Sachs analyst Salveen Richter has maintained their bullish stance on AMGN stock, giving a Buy rating yesterday.Don't Miss our Black ...

22hon MSN

Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond

Wait for longer-term data with Amgen's GLP-1, says Piper Sandler's Christopher Raymond ...

1don MSN

These Stocks Are Moving the Most Today: GM, Ford, Amgen, Eli Lilly, Super Micro, Best Buy, Rivian, NRG Energy, Kohl’s, Semtech, and More

Shares of General Motors and Ford fall after President-elect Donald Trump announces his tariff plans, while Amgen tumbles as ...

3h

Evan Seigerman Recommends Buy on Amgen Due to Promising MariTide Trial Results and Strategic Growth Moves

Analyst Evan Seigerman from BMO Capital maintained a Buy rating on Amgen (AMGN – Research Report) and keeping the price target at $362.00.Don't ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results